Markets · 1 sources covering this

Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·2h ago
Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion
Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/1dafdd61609201ff0860bc0497d813cd70b7c7fb"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion"></iframe>

Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

How 1 sources are covering this

Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

More from Markets

Democrats Sweep House and Senate in Midterm Rebuke of Trump

European Defense Stocks Slide as Democrats’ Sweep Dents Optimism

Stock Bulls Are Glad This Election Is Finally Over

India Approves Plan to Absorb More Short-Term Military Recruits

Reader

Trust & legal

Across the network